Market Waking Up to Abbvie's (ABBV) Strong Pipeline - Jefferies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Goldman Sachs Raises PT on Abbvie (ABBV) to $52
April 29, 2013 10:45 AM EDTGoldman Sachs today maintained a Buy rating on Abbvie (NYSE: ABBV) and raised its price target to $52.00 (from $45.00). Analyst Jami Rubin said he had greater confidence in Humira growth and in Abbvie's pipeline.
"We estimate that in a best case... More
Abbvie, Inc. (ABBV) Tops Q1 EPS by 1c; Reaffirms Outlook
April 26, 2013 7:52 AM EDT(Updated - April 26, 2013 7:59 AM EDT)
AbbVie (NYSE: ABBV) reported Q1 EPS of $0.68, $0.01 better than the analyst estimate of $0.67. Revenue for the quarter came in at $4.33 billion, versus $4.17 billion reported last year.
On an operational basis, sales increased 5.1 percent, excluding a 1.4 percent unfavorable impact from foreign exchange rate... More
